Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trialHugo Ford, Janet Dunn, Andrea Marshall et al.|The Lancet Oncology|2013Cited by 604
Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trialNalinie Joharatnam‐Hogan, R. Steele, Nicola Warner et al.|The Lancet. Gastroenterology & hepatology|2019Cited by 64
Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trialsAlicia Okines, Andrew Wotherspoon, David González de Castro et al.|European Journal of Cancer|2013Cited by 40
COUGAR-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma.Hugo Ford, Janet Dunn, Andrea Marshall et al.|Journal of Clinical Oncology|2013Cited by 32